Table 2.
Participant Characteristics
| Total | IE | LHT | ||||
|---|---|---|---|---|---|---|
| Characteristic | Survivors (N=28) M (SD) |
Partners (N=28) M (SD) |
Survivors (N=19) M (SD) |
Partners (N=19) M (SD) |
Survivors (N=9) M (SD) |
Partners (N=9) M (SD) |
| Age | 54.1 (10.8) | 54.8 (10.0) | 54.8 (10.4) | 55.1 (10.4) | 52.7 (12.3) | 54.0 (9.5) |
| Sexual concerns [0–10] | 6.0 (2.4) | 5.9 (2.2) | 6.3 (3.0) | |||
| Length of relationship (years) | 25.9 (14.1) | 29.0 (12.5) | 19.6 (16.0) | |||
| Time since diagnosis (months) | 32.1 (15.8) | 34.6 (16.3) | 26.7 (14.0) | |||
| Time since treatment completion (months) | 22.7 (14.3) | 24.6 (14.5) | 18.7 (14.0) | |||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Charlson Comorbidity Score | ||||||
| No comorbidities | 20 (71.4%) | 21 (75%) | 12 (63.2%) | 15 (78.9%) | 8 (88.9%) | 6 (66.7%) |
| One comorbidity | 6 (21.4%) | 6 (21.4%) | 5 (26.3%) | 3 (15.8%) | 1 (11.1%) | 3 (33.3%) |
| Two or more comorbidities | 2 (7.1%) | 1 (3.6%) | 2 (10.5%) | 1 (5.3%) | 0 (0%) | 0 (0%) |
| Race | ||||||
| White/Caucasian | 25 (89.3%) | 24 (85.7%) | 17 (89.5%) | 16 (84.2%) | 8 (88.9%) | 8 (88.9%) |
| Black/African American | 1 (3.6%) | 3 (10.7%) | 1 (5.3%) | 3 (15.8%) | 0 (0%) | 0 (0%) |
| Asian | 1 (3.6%) | 1 (3.6%) | 0 (0%) | 0 (0%) | 1 (11.1%) | 1 (11.1%) |
| More than one race | 1 (3.6%) | 0 (0%) | 1 (5.3%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Education | ||||||
| High School or GED | 4 (14.3%) | 3 (10.7%) | 2 (10.5%) | 3 (15.8%) | 2 (22.2%) | 0 (0%) |
| Some college | 6 (21.4%) | 6 (21.4%) | 4 (21.1%) | 4 (21.1%) | 2 (22.2%) | 2 (22.2%) |
| Completed college/Graduate school | 18 (64.3%) | 19 (67.8%) | 13 (68.4%) | 12 (63.2%) | 5 (55.6%) | 7 (77.8%) |
| Employment Status | ||||||
| Full/Part Time | 18 (64.3%) | 21 (75%) | 11 (57.9%) | 12 (63.2%) | 7 (77.8%) | 9 (100%) |
| Retired | 3 (10.7%) | 4 (14.3%) | 2 (10.5%) | 4 (21.1%) | 1 (11.1%) | 0 (0%) |
| Self-employed | 3 (10.7%) | 3 (10.7%) | 3 (15.8%) | 3 (15.8%) | 0 (0%) | 0 (0%) |
| Unemployed/on disability/other | 4 (14.2%) | 0 (0%) | 3 (15.8%) | 0 (0%) | 1 (11.1%) | 0 (0%) |
| Sexual Orientation | ||||||
| Heterosexual/Straight | 27 (96.4%) | 19 (100%) | 8 (88.9%) | |||
| Homosexual/Lesbian | 1 (3.6%) | 0 (0%) | 1 (11.1%) | |||
| Marital Status | ||||||
| Married | 27 (96.4%) | 19 (100%) | 8 (88.9%) | |||
| Living with a significant partner but not married | 1 (3.6%) | 0 (0%) | 1 (11.1%) | |||
| Menopausal Status | ||||||
| Premenopausal | 4 (14.3%) | 2 (10.5%) | 2 (22.2%) | |||
| Perimenopausal | 2 (7.1%) | 1 (5.3%) | 1 (11.1%) | |||
| Post-menopausal | 22 (78.6%) | 16 (84.2%) | 6 (66.7%) | |||
| Disease stage | ||||||
| Stage I | 12 (42.9%) | 6 (31.6%) | 6 (66.7%) | |||
| Stage II | 11 (39.3%) | 8 (42.1%) | 3 (33.3%) | |||
| Stage III | 5 (17.9%) | 5 (26.3%) | 0 (0%) | |||
| Primary Surgery | ||||||
| Lumpectomy | 17 (60.7%) | 11 (57.9%) | 7 (77.8%) | |||
| Mastectomy | 11 (39.3%) | 8 (42.1%) | 2 (22.2%) | |||
| Treatments Received | ||||||
| Chemotherapy | 17 (60.7%) | 14 (73.7%) | 3 (33.3%) | |||
| Radiation | 21 (75%) | 15 (78.9%) | 6 (66.7%) | |||
| Hormonal Therapy | 22 (78.6%) | 14 (73.7%) | 8 (88.9%) | |||
| Tamoxifen | 9 (32.1%) | 6 (27.3%) | 3 (33.3%) | |||
| Aromatase Inhibitor | 13 (46.4%) | 8 (36.4%) | 5 (55.6%) | |||